Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study

Datta-Mannan A, Moser B, Xu W, Jackson K, Witcher J, Armstrong AW, Blauvelt A, Lio PA. Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study. Clin Ther. 2025 Jan;47(1):55-61. Published online December 4, 2024. doi:10.1016/j.clinthera.2024.10.016. | PMID: N/A

This study evaluated the pharmacokinetics of lebrikizumab administered subcutaneously via prefilled syringe or autoinjector in healthy volunteers, assessing absorption and exposure characteristics.

Key Learning Points

• •
  Lebrikizumab shows consistent pharmacokinetic profiles when administered via prefilled syringe or autoinjector in healthy subjects.
• •
  Both delivery methods are well tolerated with no significant differences in safety or immunogenicity.